A point-prevalence survey of antimicrobial utilisation within New Brunswick hospitals to focus antimicrobial stewardship efforts and decrease low-value care by Brideau-Laughlin, Diane
  
Université de Montréal 
 
A point-prevalence survey of antimicrobial utilisation within New Brunswick hospitals  
to focus antimicrobial stewardship efforts and decrease low-value care 
 
 
par Diane Brideau-Laughlin 
 
Département d’administration de la santé 
École de santé publique 
 
 
Mémoire présenté à la Faculté de santé publique en vue de 
l’obtention du grade de M.SC. en évaluation des technologies de la santé 
 
 
Septembre 2014 
 
© Diane Brideau-Laughlin 2014
 
i 
 
RESUME 
Introduction: Il est important de minimiser le gaspillage et les risques associés aux soins sans 
valeur. La gestion de l’utilisation des antimicrobiens vise à optimiser leur emploi et doit être 
adaptée au milieu et à sa population.  
Objectifs: Évaluer les profiles d’utilisation actuels des antimicrobiens et fixer des objectifs pour 
les interventions en matière de gestion des antimicrobiens. 
Méthode: Vingt-et-un hôpitaux  du Nouveau-Brunswick offrant des soins de courte durée en 
médecine générale, en chirurgie et en pédiatrie ont pris part à une enquête sur la prévalence 
ponctuelle. Tous les patients admis aux hôpitaux participants et ayant reçu au moins un 
antimicrobien systémique ont été inscrits à l’étude. Les principaux critères d’évaluation étaient 
le profil d’utilisation, selon l’indication et l’antimicrobien prescrit, le bienfondé de l’utilisation et 
la durée de la prophylaxie chirurgicale. Des statistiques descriptives  et un test d’indépendance 
Χ2  furent utilisés pour l’analyse de données.  
Résultats: L’enquête a été menée de juin  à août 2012. Un total de 2244  patients ont été admis 
pendant la durée de l’étude et 529 (23,6%) ont reçu un antimicrobien.  Au total, 691 
antimicrobiens ont été prescrits, soit 587 (85%) pour le traitement et 104 (15%) pour la 
prophylaxie. Les antimicrobiens les plus souvent prescrits pour le traitement (n=587) étaient 
des classes suivantes : quinolones (25,6%), pénicillines à spectre étendu (10,2%) et 
métronidazole (8,5%).  Les indications les plus courantes du traitement étaient la pneumonie 
(30%), les infections gastro-intestinales (16%) et les infections de la peau et des tissus mous 
(14%). Selon des critères définis au préalable, 23% (n=134) des ordonnances pour le traitement 
étaient inappropriées et 20% (n=120) n’avaient aucune indication de documentée. Les 
domaines où les ordonnances étaient inappropriées étaient les suivants : défaut de passage de 
la voie intraveineuse à la voie orale (n=34, 6%), mauvaise dose (n=30, 5%), traitement d’une 
bactériurie asymptomatique (n=24, 4%) et doublement inutile (n=22, 4%). Dans 33% (n=27) des 
cas, les ordonnances pour la prophylaxie chirurgicale étaient pour une période de plus de 24 
heures.  
Conclusions: Les résultats démontrent que les efforts de gestion des antimicrobiens doivent se 
concentrer sur les interventions conventionnelles de gestion de l’utilisation des antimicrobiens, 
l’amélioration de la documentation, l’optimisation de l’utilisation des quinolones et la réduction 
au minimum de la durée de la prophylaxie chirurgicale.  
Mots clés: gestion de l’utilisation des antimicrobiens, prévalence ponctuelle, utilisation des 
antimicrobiens, utilisation appropriée, soins sans valeur   
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ABSTRACT  
Introduction:  Low-value practices should be stopped as they lead to waste and possible harm. 
Antimicrobial stewardship (AS) aims at optimizing antimicrobial prescribing and should be 
tailored to local needs. 
Objectives:  To assess current patterns of antimicrobial utilisation and identify targets for AS 
interventions. 
Methods:  A point prevalence survey was completed in 21 hospitals in New Brunswick, Canada.  
All admitted patients at the time of the survey and receiving at least one systemic antimicrobial 
were included.  Main outcome measures included patterns and appropriateness of utilisation, 
and duration of surgical prophylaxis.  Descriptive statistics and Chi-squared test of 
independence were used to analyse data. 
Results: The survey was completed between June and August 2012. Of 2244 eligible patients, 
529 (23.6%) were on antimicrobials.  A total of 691 antimicrobials were prescribed, 587 (85%) 
for treatment, 104 (15%) for prophylaxis. Within the treatment group (n=587) the most 
frequently prescribed classes were fluoroquinolones (25.6%), extended-spectrum penicillins 
(10.2%) and metronidazole (8.5%). The most common treatment indications were pneumonia 
(30%), gastrointestinal infections (16%), and skin and soft tissue infections (14%). Based on 
predefined criteria 23% (n=134) of the treatment orders were inappropriate and 20% (n=120) 
had no documented indication.  Areas of inappropriateness included not switched from IV-to-
PO (n=34, 6%), inappropriate dose (n=30, 5%), treatment of asymptomatic bacteriuria (n=24, 
4%) and inappropriate duplication (n=22, 4%); 33% (n=27) of surgical prophylaxis orders 
exceeded 24 hours.   
Conclusions: The findings support AS efforts focused on established AS interventions, improved 
documentation, optimised fluoroquinolone use, and minimized length of surgical prophylaxis.  
Keywords: antimicrobial stewardship, point prevalence survey, antimicrobial utilization, 
appropriateness of utilization, low-value care 
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CHAPTER 1. INTRODUCTION 
New Brunswick (NB), with a population of approximately 750,000, was recently amalgamated 
into two health authorities: Horizon Health Network (Horizon) and Vitalité Health Network 
(Vitalité). Horizon, a 1606-bed multi-hospital network, is the largest health-care organization in 
Atlantic Canada, serving NB, northern Nova Scotia and Prince Edward Island. Vitalité is also a 
multi-hospital network, serving primarily the francophone population of the province. Both 
regions include university hospitals, tertiary services and well as community hospitals. Within 
this context, systems from the various regions are entering into new affiliation agreements and 
their care practices are being reviewed and harmonized, therefore moving the province 
towards a more fully integrated health care system. 
 
An important example of such harmonization is the NB Provincial Drugs and Therapeutics (D&T) 
Committee with its subcommittee, the NB Provincial Health Authorities Anti-Infective 
Stewardship Committee (ASC). The latter has the mandate to advise on all matters relating to 
the use of antimicrobials within the regional health authorities (Appendix 1).  Its purpose is to 
make evidence-informed recommendations to the provincial D&T Committee regarding 
effective, safe and cost-effective choices of anti-infective agents to include within the provincial 
hospital formulary as well as the conditions and/or criteria for their use when appropriate, 
therefore acting as steward of this limited therapeutic resource.  The ASC also has the mandate 
to develop and maintain an Antimicrobial Stewardship Program and to undertake reviews of 
antimicrobial utilisation with the goal to ensure their most clinically appropriate use with 
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regards to efficacy, toxicity and resistance patterns and make recommendations as appropriate. 
Ideal drug usage has been described as using “the right drug, administered by the best route, in 
the right amount, at the optimal interval, for the appropriate period, after an accurate 
diagnosis”. (1) Recognizing that local, regional, national and international variations in 
antimicrobial prescribing practices exist and they are influenced by both cultural and 
behavioural determinants (2), the AS program aims towards interventions that are measurable 
and guided by  international as well as local evidence. 
 
Creating an AS program requires acquiring baseline information, including institutional use. (3) 
This helps identify recurrent problems with antimicrobial use at the institution-level and frame 
the problems that need to be addressed (e.g. failure to discontinue surgical antibiotic 
prophylaxis, vancomycin therapy for a single coagulase-negative Staphylococcus species blood 
culture, combination therapy for all gram-negative infections). (3, 4) Prior to this project no 
data were available to accurately assess antimicrobial utilisation within NB hospitals. Without 
these data, the NB Provincial Health Authorities ASC had no baseline against which to develop 
targeted AS interventions and against which to measure the effectiveness of such interventions. 
As a means to acquire these data, the ASC recommended the completion of a point prevalence 
survey in all eligible NB hospitals and across all services. To our knowledge, this is the first time 
such a large number of antimicrobial orders were reviewed over such a broad area of care 
within a health system in Canada.  
3 
 
CHAPTER 2. LITERATURE REVIEW 
2.1 Influencing Prescribing Patterns 
Research has shown that in the absence of a clear diagnosis, physicians oftentimes prescribe 
antimicrobials to be “on the safe side” or to prevent secondary bacterial infections. (5,6) 
Prescribing by physicians is believed to be influenced by factors such as cultural beliefs of the 
patient and the prescriber, patient-driven demand, socioeconomic factors, clinical autonomy as 
well as diagnostic uncertainty. (2, 6, 7) Strategies that have been used to influence prescribing 
include production of guidelines, development of multidisciplinary teams and an emphasis on 
education. (8) Despite such measures, personal experience has been shown to have a high 
degree of influence on physician prescribing patterns, at times contradicting evidence-based 
literature, and has led to less than optimal perceptions regarding such guidelines. (8)  
 
A recent Cochrane review was performed and included interventions aimed at improving 
antimicrobial prescribing. (9) Both persuasive and restrictive interventions were reviewed. The 
persuasive interventions advised physicians on how to prescribe and provided them with 
feedback on their prescriptive habits; whereas the restrictive interventions aimed at limiting 
their prescriptive autonomy. An example of a restrictive intervention is the need for a physician 
to obtain approval from an infectious diseases (ID) specialist prior to or shorting after initiating 
an antimicrobial order.  Restrictive interventions were found to have a significantly greater 
impact on prescribing outcomes at one month (32%, 95% confidence interval (CI) 2-61%, 
p=0.03) and on microbial outcomes at 6 months (53%, 95% CI 31-75%, p=0.001) but this 
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difference was no longer apparent at 12 or 24 months. (9). The authors performed a meta-
analysis and concluded that restrictive interventions are most effective when the need is urgent 
but that after six months, persuasive and restrictive interventions are equally effective. In their 
review of the effectiveness of the persuasive audit and feedback intervention, Ivers and 
colleagues performed a multivariable meta-regression analysis and reported that feedback may 
be more effective when the baseline performance is low, the source of the feedback is a 
colleague or a superior, the feedback is provided several times and in multiple formats 
(verbal/written) and includes explicit targets and an action plan. (10) Any choice of intervention 
requires baseline data against which to measure its effectiveness. (2) 
2.2  Low-Value Health Care: Disinvestment 
Headlines throughout the developed world reflect concern related to the swelling cost of 
providing health services. In Canada, during the period from 1998 to 2008, public-sector 
spending on health grew at more than double the rate of revenue growth. (11) Total spending 
on health care in Canada was projected to reach $200 billion (CAD) in 2011, representing a 
health to gross domestic product (GDP) ratio of 8.1 percent. (11) Total expenditures for hospital 
services alone were $49.5 billion (CAD) in 2008 and were expected to rise to $58.4 billion (CAD) 
in 2011 or 3.4% of the GDP. (12)  Older data estimate the annual costs of managing a 
methicillin-resistant Staphylococcus aureus (MRSA)  colonized or infection patient to be $1363 
(CAD) and $14 360 (CAD) respectively, the total for all Canadian hospitals being $42-$59 million 
(CAD). (13) Incremental costs for managing vancomycin-resistant enterococcus (VRE)-colonized 
patients were estimated at $6732 (CAD) per patient or $5 to $16 million for all Canadian 
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hospitals. (13) A model to assess the financial cost of antimicrobial resistance estimates the 
resistant microorganisms add approximately $25 to $40 million (CAD) annually in direct 
hospitalization costs in Canada (13)  
 
Coupled with increases in costs and utilisation are questions relating to the effectiveness of 
many of the services provided. In the early 1990’s reports suggested that 20% to 25% of 
patients received treatments deemed unnecessary and possibly harmful while 30% to 40% of 
patients did not receive treatment with proven effectiveness. (14, 15) It is generally recognized 
that up to 50% of antimicrobial use may be inappropriate, adding considerable cost to patient 
care and microbial resistance. (16-18) In the hospital environment 30 to 50% of antimicrobial 
use may be unnecessary or inappropriate, the broadest spectrum antimicrobials are commonly 
used and the most dangerous drug resistance is seen. (19, 20)  Despite this, there are limited 
processes in place to identify, reduce or withdraw health technologies and practices which are 
obsolete, ineffective or inappropriate therefore remaining unnoticed by those who are involved 
in administrative and policy decision and resulting in suboptimal care and ineffective resource 
allocation. (21, 22)   
 
The term disinvestment first appears in the health care literature about 20 years ago and it 
advocates a more objective, evidence-informed approach to resource allocation. (15)  Efforts 
such as the Choosing Wisely initiative in the United States (US) (www.choosingwisely.org ) , the 
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“Do Not Do” recommendations from the United Kingdom National Institute for Health and Care 
Excellence (www.nice.org) and recently the Canadian version of the Choosing Wisely campaign 
(www.choosingwiselycanada.org ) are all proponents of health care provision that is based in 
evidence and critical of low-value interventions.  While value in health care has been defined as 
“the framework for performance improvement” (23), low-value care has been defined as care 
that delivers “marginal benefit, be it through overuse, misuse or waste.” (14)  Disinvestment as 
understood in the context of low-value interventions should be considered part of a broader 
agenda to improve appropriateness, efficiency and quality, ensuring that the right patient 
receive the right care at the right time, at the right place and in the right way by the right 
person. (15) 
2.3  Antimicrobial resistance 
Despite the availability of antimicrobials, infectious diseases remain the second-leading cause 
of death world-wide, the third leading cause of death in the US (16) and the seventh in Canada. 
(17) Infections caused by antimicrobial-resistant organisms have been associated with 
increased length of hospital stay, increased mortality and increased costs of care. (19, 28) Use 
of antimicrobials selectively favours the propagation of resistant organisms and hospitals play a 
key role in this. (29, 30) In Europe, bloodstream infections due to third-generation 
cephalosporin-resistant Escherichia coli resulted in an increase in 30-day all-cause and hospital-
stay mortality and an estimated 5-day increase in hospital stays. (28) In similar settings, MRSA 
patients had higher hospital-stay mortality, 30-day all-cause mortality and an 8.6-day increase 
7 
 
in length of stay compared to patients with methicillin-sensitive Staphylococcus aureus. (31) 
 
In Canada, MRSA was first reported in 1981. (30) Data from the Canadian Nosocomial Infection 
Surveillance Program report increases in MRSA isolates from 0.95 per 100 isolates in 1995 to 
8.1 per 100 isolates in 2002. (30)  The first isolate of VRE appeared in Canada in 1993. (30) 
While the rate of VRE in Canada has not attained that of the US, it has been isolated in all 10 
provinces. (30) Between 1998 and 2002, the rate of VRE in Canadian hospitals, while increased, 
was at 0.5 per 1000 patients admitted compared to the US data of 12 per 100 patients 
admitted. (32) Incident rates of penicillin-, trimethoprim-sulfamethoxazole-, macrolide-, 
clindamycin- and fluoroquinolone-resistant Streptococcus pneumoniae  have increased 
markedly. (33) During the period between 1988 and 2001, rates of penicillin resistance 
increased from zero to 7% and rates of trimethoprim-sulfamethoxazole resistance increased 
from 3.7% to 12%. (33) Incidence of macrolide- and clindamycin-resistant isolates of 
Streptococcus pneumoniae has increased from 1.2% to 13.1% and 1.2% to 5.8% respectively 
during the same 13-year period. (33)  Canada reports resistance rates to ciprofloxacin, 
levofloxacin and moxifloxacin  of 1.8%, 0.7% and 0.3% respectively. (33) In patients 65 years of 
age or older, the rates of levofloxacin- and ciprofloxacin-resistant Streptococcus pneumoniae  
increased from zero to 4.3% and from zero to 7.2% respectively. (33) At present, the major 
multi-drug resistant gram-negative pathogen isolated in Canadian hospitals is Pseudomonas 
aeruginosa. (34, 35) About 30% of Pseudomonas isolates from Canadian and US intensive care 
units (ICU) are resistant to fluoroquinolones. (34) In Canada, 14% of intensive care unit (ICU) 
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Pseudomonas isolates demonstrate carbapenem resistance and about 13% of ICU 
Pseudomonas isolates are multi-drug resistant. (34) 
 
Internationally, use of fluoroquinolones has been associated with increased rates of 
Staphylococcus aureus and Pseudomonas resistance to fluoroquinolones but also to 
carbapenems, amikacin and other antimicrobial classes of drugs. (36-38) The European 
Surveillance of Antimicrobial Consumption (ESAC) reports that during the period 2000-2005, 
the use of fluoroquinolones increased by 15% or more in almost half of the participating 
countries. (39) Concomitantly, fluoroquinolone resistance in E. coli increased from 5% to 14% 
during the period 2001-2004 and from 4% in 2005 to 8% in 2008 for Klebsiella pneumoniae 
isolates. (39) 
 
Three general categories of antimicrobial-related drivers of resistance have been identified: the 
inappropriate or over-use of antimicrobials, sub-therapeutic exposure to an antimicrobial for 
long treatment periods and the use of low-potency antimicrobials. (30, 34-35) The emergence 
of antimicrobial-resistant organisms has prompted organizations such as the US Center for 
Disease Control and Prevention (CDC) (www.cdc.org ), the European Centre for Disease Control 
and Prevention (ECDC) (www.ecdc.europa.eu ) and the World Health Organization 
(www.who.org ) and recently the Canadian Paediatric Society (CPS) (www.cps.ca ) to send call 
to arms messages to heighten awareness of the public health concerns linked to the 
mismanagement of antimicrobials. These organizations caution that without a more judicious 
9 
 
approach to antimicrobial utilisation, antibiotic resistance threatens to return us to an era when 
even simple infections were fatal.  
2.4  Pathogenic Selection 
Another unintended consequence of antimicrobial use is the selection of pathogenic organisms. 
(40) Patients who are hospitalized and prescribed antimicrobials are at increased risk of 
developing Clostridium difficile-associated-diarrhoea (CDAD) due to normal intestinal flora 
disturbance. (41) In 2003, over 7000 cases of nosocomial CDAD were reported in Quebec 
hospitals. (42) In 2005, the reported incidence from 30 Quebec hospitals was 15 cases or more 
per 10,000 patient days, 5 times higher than the historic incidence. (42) A multivariate analysis 
of these data identified age, duration of hospitalization, a previous episode of CDAD and having 
received fluoroquinolones, cephalosporins, macrolides, clindamycin or intravenous beta-
lactam/beta-lactamase inhibitors as independent risk factors to the development of CDAD. (42) 
Prolonged  (7 days or longer) use of fluoroquinolones, first-generation cephalosporins, 
cefuroxime, clindamycin and macrolides also increased the risk of CDAD. (42)  It is estimated 
that for every 10 patients that acquire CDAD in hospital, 1 patient will die. (43)  The estimated 
increase in risk of dying in patients with hospital-acquired CDAD is 3-fold. (43) Patients with 
CDAD are more likely to have prolonged hospital stays; they are more likely to remain in 
hospital at 7 and 28 days compared to non-infected patients (Canadian data). (44) The median 
increase in length of stay attributable to CDAD is 6 days. (44) 
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While increasing antimicrobial resistance has created a critical need for the development of 
new antibiotics with novel mechanisms of action, the pharmaceutical industry has paradoxically 
been abandoning this area of research to focus on chronic disease therapies. (4, 26, 34) Since 
1998, only ten new antimicrobials had been approved in the US and only two of these (linezolid 
and daptomycin) actually had new targets of action. (20) The main reasons cited for this 
decrease in interest are that “drug development is risky and expensive and drugs to treat 
infections are not as profitable as those that treat chronic disease.” (20)  
 
2.5  Antimicrobial Stewardship 
Antimicrobial stewardship (AS) has been defined as ensuring patients get the right 
antimicrobials when they need them (and only when they need them). (17) It has been 
described as optimal antimicrobial utilisation by using “the right antimicrobial at the right time, 
at the right dose and for the right duration”. (45) Similarity with the themes of disinvestment of 
low-value care are striking and reflect a  need for an evidence-based approach to prescribing 
resulting in optimal utilisation as defined by Brundtland.  (1)  
 
Recognizing every antimicrobial order represents a balance of benefits and risks, AS efforts 
focus on appropriate use of antimicrobials while attempting to limit unwanted consequences of 
their use such as antimicrobial resistance, pathogenic selection and drug-related or 
administration-related adverse reactions. (17, 46). In 2007, the Infectious Diseases Society of 
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America (IDSA) published guidelines for supporting AS programs as a means to conserve the 
antimicrobials currently available. (17) A recent review of the literature on the impact of AS 
programs in critical care areas supports the conclusion that within these areas of care they 
result in improved antimicrobial utilisation, rates of resistance and limited adverse events while 
not negatively impacting short-term clinical outcomes. (19)  
 
Antimicrobial stewardship interventions include such activities as clinical audit and feedback, a 
formulary of targeted antimicrobials and approved indications, education, antimicrobial order 
forms, guidelines and clinical pathways for antimicrobial utilization, strategies for streamlining 
or de-escalation of therapy, dose optimization and intravenous (IV) to oral (PO) conversion 
where appropriate. (17, 40) 
 
2.6  Antimicrobial Stewardship Efforts in Canada 
Although widespread resistance to first line antimicrobials is accelerating rapidly worldwide, 
rates differ considerably from country to country and among geographic regions of larger 
nations such as Canada. (47) While Canada still enjoys considerably lower rates of resistance 
than the US, it has substantially higher rates than other developed nations such as Denmark 
and Iceland. (48) 
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Systematic efforts for controlling antimicrobial resistance in Canada began in 1997 following a 
national consensus conference held in Montreal entitled “Controlling Antimicrobial Resistance: 
An Integrated Action Plan for Canadians”. (13) The conference, co-sponsored by Health Canada 
and the Canadian Infectious Disease Society, developed a plan which emphasized three core 
areas: AS, surveillance to monitor resistance trends and infection prevention and control. (13)  
In the 2012 edition, Accreditation Canada’s Qmentum Program updated its Managing 
Medications section to include a new Required Organizational Practice: ROP 1.3: “the 
organization has a program for AS to optimize antimicrobial use”. (40) 
 
Because death rates from hospital-acquired infections are higher than those associated with 
most community-acquired infections, and rates of antimicrobial use are generally higher in 
patients admitted to critical care units, most of the AS efforts in Canada and elsewhere have 
been focused in the critical care environment. (19, 49-52)  Studies in Canada have reported 
improved microbiologically targeted antimicrobial utilisation, decreased antimicrobial costs, 
decreased use of antipseudomonal agents and improved documentation following the 
introduction of AS programs within the intensive care area in both tertiary and community 
hospitals. (51-52) 
 
2.7  Point Prevalence Surveys 
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Point prevalence surveys (PPS) have been used to provide information about antimicrobial use 
and to assess the impact of interventions such as antibiotic policies. (53-54) Such surveys have 
been documented for over 30 years; they can identify targets for improvement in antimicrobial 
prescribing. (54-55) PPS can help stewardship teams focus on clinical scenarios where overuse 
is common, where opportunities to de-escalate are missed, and where it can be possible to stop 
antimicrobial therapy when appropriate. (56) Repeated PPS have been used for the evaluation 
of infection control programs, to follow trends in hospital-acquired infections, determine rates 
of device utilisation and antibiotic usage, for intra-hospital comparisons, to measure adverse 
effects of hospital-acquired infections and to measure costs associated with these infections. 
(56-57) In Canada, PPS have  focused primarily on surveillance of nosocomial infection rates 
through the Canadian Nosocomial Infection Surveillance Program (www.phac-aspc.gc.ca/nois-
sinp/survprog-eng.php ) and one article was identified in the literature that reports on the 
prevalence of nosocomial infections within Canadian adult acute-care hospitals. (56)  While not 
focusing on overall antimicrobial utilisation, the authors do report on the percent of patients 
admitted to the participating hospitals who were on antimicrobials and the most frequently 
used antimicrobials (burden of utilisation).  No Canadian PPS reports on antimicrobial utilisation 
with appropriateness evaluation were found in the literature.  
 
The European Surveillance of Antimicrobial Consumption (ESAC) was established in 2000 and 
the initial phase included hospital-based information from only 15 hospitals and did not provide 
reliable data regarding bed occupation or patient admissions. (54) The second phase of the 
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project aimed at capturing more detailed information related to hospital utilisation and to 
establish the first standardized European PPS. (54) 
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CHAPTER 3. OBJECTIVES AND RESEARCH QUESTIONS 
 
Despite the fact that NB has access to information-generating technologies, no database is 
currently available that allows accurate assessment of antimicrobial utilisation within NB 
hospitals. Analysis of these data to assess appropriateness is the baseline required to develop 
targeted AS interventions and against which to measure the effectiveness of these 
interventions.  
3. 1  Research Questions 
1. What are the current patterns of antimicrobial usage within NB hospitals with respect 
to patient characteristics, indication, prescribed daily dose, route and prescriber? 
2. Based on antimicrobial usage patterns, where do opportunities exist to improve 
patient outcome and safety through implementation of targeted AS interventions within 
NB hospitals? 
3.2  Primary research objective 
Determine antimicrobial usage patterns within all NB hospitals with 10 or more acute care 
beds. 
3.3  Secondary research objectives 
Determine the proportion of antimicrobial orders within NB hospitals that are appropriate 
based on pre-defined criteria. 
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Determine the proportion of antimicrobial orders within NB hospitals that would be 
appropriate for targeted antimicrobial stewardship interventions. 
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CHAPTER 4. METHOD 
4.1  Study Design 
A point prevalence survey (PPS) method and data collection tool (see Appendix 2) were 
adapted from the ESAC PPS described by Ansari et al.  and modified to meet local needs. (54) 
The survey was designed to gather data about all systemic antimicrobials prescribed within NB 
hospitals, including the antimicrobial itself, the indication(s) for the therapy, the patient and 
any patient-specific characteristics that could potentially influence the choice, the route of 
administration or the dose of the antimicrobial, the timing of the first dose with respect to the 
patient’s hospitalisation, whether the antimicrobial was used for therapeutic purposes or for 
prophylaxis, the type of prescriber, whether prescribers had access to or had utilised the 
support of an ID specialist and whether microbiological data were utilised to support 
antimicrobial choices as appropriate. Microbiology culture reports were deemed relevant if 
representative of the site being treated and if the cultures were taken within 120 hours (5 days) 
of the start of the therapy. Review and analysis of this information was used to determine 
whether the orders met pre-defined inappropriateness criteria and to identify antimicrobial 
stewardship interventions that could be implemented to improve on this use. This study was 
not designed to assess the rates of either community-acquired infections or hospital-acquired 
infections in the province. 
4.2  Study Setting and Population 
The chairperson of the NB Anti-Infective Stewardship Committee sent a memo to all eligible NB 
hospital chief executives and medical advisory committees explaining the objectives of the PPS 
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and inviting them to participate. A letter of support from the directors of pharmacy from both 
health regions was also forwarded to the pharmacy departments of all NB hospitals asking for 
administrative support if needed by the research team. 
 
The PPS was performed during the months of June, July or August 2012 and all eligible NB 
hospitals where in-patient acute, general medical, surgical or paediatric services are provided 
agreed to participate. Surgical units were surveyed on Tuesday, Wednesday or Thursday to 
capture information regarding prophylactic antimicrobial orders prescribed during the previous 
24 hours. Medical units were surveyed on Monday, Tuesday, Wednesday or Thursday. 
Depending on the number of beds and staff availability, the survey could be completed in each 
participating hospital over 1 or more days; however, all patients admitted to an administrative 
unit (e.g. all patients admitted to a specific general surgery unit) were surveyed in a single day. 
On the day of the survey, eligible patients were identified using daily pharmacy services-
generated patient-specific medication profiles and/or through daily admission census reports. 
4.2.1  Inclusion Criteria 
• All adult and paediatric patients admitted to a participating hospital patient care unit 
at the time of the survey and receiving at least one systemic1 antimicrobial2. 
                                                            
1 Systemic was defined as an antimicrobial administered via one of the following routes: oral, intravenous or 
intramuscular. 
 
2 Antimicrobial was defined as those agents included in the American Hospital Formulary Service (AHFS) 
Pharmacologic-Therapeutic Classification System classes 08:12 (Antibacterials), 08:14 (Antifungals), 08:16 
(Rifampin only), 08:30 (Metronidazole only), and 08:36 (Urinary Anti-Infectives) 
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4.2.2  Exclusion Criteria 
• Patients admitted to an emergency department 
4.3  The Research Team and Project Funding 
The research team was comprised of two ID specialist physicians, one from each health 
network, three hospital pharmacists with experience in infectious diseases (including the 
author), two from Horizon and one from Vitalité a biostatistician and two university students. 
An unrestricted research grant was received from Medbuy Canada(www.mebbuy.ca) to cover 
student salaries and travel costs.  The research protocol was authored primarily by the author 
with content support provided by the other expert team members. The statistical analysis 
method was developed with the support of the biostatistician. The funding agency had no 
direct or indirect influence on the content of the protocol, the data collection process or the 
data analysis and reporting process. 
4.4  Inappropriateness Criteria 
To the author’s knowledge, no validated tool exists to measure appropriateness of 
antimicrobial prescribing. The choice of the inappropriateness criteria was based on the ISDA 
Antimicrobial Stewardship Guidelines. (17, http://www.idsociety.org)  
 
These guidelines developed by the Infectious Diseases Society of America (IDSA) and the 
Society for Healthcare Epidemiology of America (SHEA) have become the cornerstone of most 
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North American AS programs. (17) They aim to developing AS programs that focus on 
appropriate selection, dosing, route and duration of antimicrobial therapy with a goal towards 
optimal clinical outcomes with minimal unintended consequences such as toxicity, selection of 
pathogenic organisms and emergence of resistance. (17) They have as a premise that there is a 
direct link between antimicrobial utilization and antimicrobial resistance and that the frequency 
of inappropriate antimicrobial use is an acceptable surrogate marker for avoidable resistance 
development. (17) Amongst the core elements of an AS Program, the following were deemed 
appropriate for baseline assessment with the use of a PPS: streamlining or de-escalation of 
therapy, dose optimization, parenteral to oral conversion. (17) Streamlining or de-escalating of 
therapy encourages review of culture results and other patient specific characteristics such as 
immunocompetence, co-morbidities and changing the spectrum of antimicrobial coverage as 
appropriate through either a switch to a less broad-spectrum agent or to a single agent from 
dual therapy (removal of redundant therapy as appropriate).  (17) Dose optimization is as a 
result of the review of patient-specific characteristics such as age, renal function, 
immunocompetence, site of infection, and pharmacokinetic and pharmacodynamic 
characteristics of the drug. (17)  Within this element is evaluation of the route of 
administration. Oral therapy may not be appropriate for the treatment of such infections as 
endocarditis, meningitis, osteomyelitis, or bacteraemia. (17) For antimicrobials with excellent 
oral bioavailability, a conversion from parenteral to oral therapy may be indicated provided 
clinical improvement (decrease in white blood cell count, the patient is haemodynamically 
stable, shows improved signs and symptoms), afebrile for at least 48 hours, has no evidence if 
gastrointestinal malabsorption, is not undergoing continuous nasogastric suctioning, has not 
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undergone  a gastrectomy or ileostomy, does not have a malabsorption syndrome or a 
gastrointestinal obstruction. (17) Patients are not candidates for an intravenous to oral 
conversion program if they are being treated for endocarditis, a central nervous system 
infection, osteomyelitis, bacteraemia, a severe abcess, cystic fibrosis or are febrile neutropenic. 
(17) Because the reason an antimicrobial agent is prescribed should be documented in the 
patient chart, the presence of such information is deemed important as a measure of 
appropriateness. (12)  The lack of information is considered as inappropriate since no relevant 
documentation supports the therapy. (12) 
 
Very little good evidence exists regarding duration of therapy with antimicrobial agents. 
(http://www.idsociety.org) Evidence-based guidelines do however exist regarding duration of 
surgical prophylaxis and therefore this survey aimed at gathering information regarding length 
of antimicrobial prophylaxis in surgical patients. (http://www.idsociety.org) 
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4.4.1  Inappropriateness Criteria for Treatment or Medical Prophylaxis 
(Table 1 and also see Appendix 2, 3 and 4) 
Table 1. Inappropriateness Criteria for Treatment or Medical Prophylaxis 
  
                                                            
3   Stepdown criteria 
• IV therapy  for treatment and not surgical prophylaxis 
• Clinically improved, tolerating oral feeds and medications, no evidence of malabsorption 
• Not treated for endocarditis, central nervous system infection, osteomyelitis, bacteraemia, abcess 
or cystic fibrosis 
• Not febrile neutropenia 
 
Code Inappropriateness Criteria Definition
A0 Does not meet other criteria Does not meet other inappropriateness criteria 
A1 Inappropriate therapy duplication e.g. Dual beta-lactam therapy; inappropriate double coverage 
(i.e. double coverage when culture and sensitivity (C&S) results 
are available) 
 
A2 Opportunity to de-escalate Relevant C&S results available to allow de-escalation to a more 
narrow antimicrobial agent (if allergy profile permits) 
 
A3 Bug-drug mismatch Patient on antimicrobial to which relevant C&S reports show 
resistance 
 
A4 Inappropriate dose Inappropriate dose based on patient characteristics (e.g. eGFR) 
and/or indication 
 
A5 Opportunity for intravenous (IV) to 
oral (PO) stepdown 
 
Patient must meet all criteria for stepdown3 
A6 Treatment of asymptomatic 
bacteriuria 
Treatment of a positive urine C&S in a non-pregnant 
asymptomatic patient 
 
A7 Inappropriate route Inappropriate route for indication being treated (e.g. 
endocarditis, deep abscess, central nervous system infection) 
 
A8 Inappropriate second line therapy
 
Inappropriate use of second-line therapy based on erroneous 
allergy information 
 
A9 No documented indication Therapy with no documented or identifiable indication
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4.4.2 Inappropriateness Criteria for Surgical Antimicrobial Prophylaxis  
Duration of surgical prophylaxis for a period of over 24 hours. 
 
4.5  Data Collection 
To ensure a consistent approach to data collection, a data collection form was developed which 
included pre-defined parameters and definitions. (Appendix 2 and 3) Prior to the start of the 
PPS, pilot surveys were completed to identify areas to improve the data collection process. 
Training sessions on the methods of PPS and the use of the data collection tool and database 
were completed for the survey team and assisting pharmacy services staff. The training was 
provided by the two hospital pharmacists from Horizon Health Network.  All data were 
collected by a member of the research team at the time of the survey and added to an Excel 
spreadsheet by the students. All data were checked twice at the time of entry. At the beginning 
of the survey, the students were included in the data collection group. It became quickly 
obvious that to ensure accuracy, consistency and efficiency, the hospital pharmacists were 
better equipped to locate the data needed and to navigate the patient chart (either paper-
based or electronic chart). The majority of the data were therefore collected by the three 
hospital pharmacists on the survey team. For surgical patients, details regarding prophylactic 
antimicrobials received in the previous 24-hours were also recorded and the documented 
intended duration of the order post-operatively. This allowed coding of the duration of 
prophylaxis as either 1 dose, 24-hours or less or greater than 24-hours.  No effort was made to 
ensure the documented duration was in fact the final duration of the therapy. A decision was 
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made to exclude discussion with clinical staff regarding treatment options for any given patient. 
This decision was made by the research team based on the geographic magnitude of the survey 
(the entire province of NB) and the fact that the intent was not to interfere with or provide 
guidance on the therapy choices. This decision was supported by the literature that indicates 
that PPS do not generally include such discussion (55) therefore, no discussion regarding 
appropriateness of therapy was permitted between the members of the survey team and either 
the attending physician or other members of the care team.  Members of the survey team were 
permitted to request additional information from members of the care team for clarity 
purposes only. 
4.6  Study variables 
The following variables, chosen to support analysis of the appropriateness of prescribing as 
described by the IDSA guidelines (17), were collected for all eligible patients directly from the 
patient record: 
• Patient demographics: age, sex, weight, estimated glomerular filtration rate (eGFR), co-
morbidities as defined by the Charlson Comorbidity Index4, allergies, 
immunosuppressive therapy5 
• Date of admission/ date of survey 
                                                            
4 The Charlson Comorbidity Index is a validated index that provides a measure of the burden of comorbid disease. 
Nineteen major conditions are included in the Charlson Index and are weighted based on their strength of 
association with mortality. (58) 
 
5 Immunosuppression was defined as a patient with either a haematological or solid tumour, having received or 
receiving chemotherapy, who has a congenital immunodeficiency or long-term immunosuppressive therapy 
(equivalent to prednisone 20mg/day or more for at least 2 weeks or patients with HIV infection with CD4 count 
less than 200. (www.cdc.org ) 
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• Number of antimicrobials per patient 
• Type of antimicrobial prescribed 
• Dose, route and frequency 
• Documented indication 
• Anatomical site of infection 
• Prescriber type 
• Community- vs. Hospital6 - acquired infection treatment vs. Prophylactic therapy 
• Relevant microbiological cultures 
• Documented infectious diseases consultation 
• Admission to an intensive care unit 
• Mechanical ventilation insertion 
• Presence of a urinary catheter 
• Stepdown criteria (see Data Collection Tool, Appendix 2) 
• Urinary tract infection criteria (see Data Collection Tool, Appendix 2) 
4.7  Data Analysis 
Assessment of the appropriateness of therapy was performed independently by the infectious 
disease specialists and the hospital pharmacists with experience in infectious disease through 
the application of pre-defined criteria (Appendix 4).  Final conclusions regarding attribution of 
the inappropriateness criteria were reached through consensus.  No information was retained 
                                                            
6 Hospital-Acquired infection was defined as symptoms starting > 48 hours after admission  and/or procedure 
performed in hospital as per the US CDC (www.cdc.org  )  
26 
 
regarding the number of assessments that required discussion as the overall number was very 
low. Of interest, the hospital pharmacists were more apt to accept documented symptoms (e.g. 
“acute abdomen”, “Increased frequency”) as a diagnosis than the physicians were.  Following 
discussion early in the review process, symptom only documentation was deemed inadequate 
and therefore judged to have no documented indication. 
 
Throughout the data analysis four denominators were used: patients, indications for therapy 
(treatment vs. prophylaxis), diagnosis and antimicrobial administered. Each patient could have 
more than one indication or diagnosis and could have more than one antimicrobial prescribed. 
Only those orders with a documented indication were included in the inappropriateness criteria 
analysis. 
 
Descriptive statistics (mean and standard deviation) were used to describe the patient 
population and to compare between-hospital and between-health region point estimates of 
antimicrobial use. Sums and percentages were used to describe antimicrobial utilisation 
patterns.  Chi squared test of independence was performed to assess the impact of an 
infectious diseases consultation. A p value < 0.05 was deemed statistically significant.  
Data were analysed using R language for statistical computing. (59) 
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4.8  Research Ethics Approval 
This project was submitted to and received ethical approval from both the Horizon Health 
Network Research Ethics Board (Appendix 5) and the Comité d’éthique de la recherche du 
Réseau de santé Vitalité (Appendix 6). 
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CHAPTER 5. RESULTS 
5.1 Results 
The PPS was completed between June and August 2012. Twenty-one of 22 (95.5%) NB hospitals 
met the eligibility criteria and were included in the survey. A total of 2244 patients were 
admitted at the time of the survey and 529 (23.6%) were on systemic antimicrobial therapy. 
(Table 1) 211/2244 patients (9.4%) were receiving treatment for hospital-acquired infections. 
The mean age of the patients included was 67.1, the mean Charlson index value was 6.2 and 
the mean number of antimicrobials prescribed per patient was 1.3.  
 
A total of 691 antimicrobials were prescribed: 326 (47.2%) for community-acquired infections, 
261 (37.8%) for hospital-acquired infections, 82 (11.9%) for surgical prophylaxis and 22 (3.2%) 
for medical prophylaxis. (Table 2) The majority of patients were prescribed one antimicrobial 
(390/529, 73.7%), 119/529, 22.5% were prescribed two antimicrobials and 20/529, 3.8% were  
on three or more agents. The average number of antimicrobial per patient was 1.3. Of the 
patients receiving three or more antimicrobials, 9/20, 45% met the criteria for being 
immunocompromised.  
 
The majority (238/691, 34.4%) of antimicrobial prescriptions were ordered by members of the 
family practice category of physicians. (Table 3) Surgeons ordered 173/691 (25.0%) and internal 
medicine specialists (excluding infectious diseases) ordered 99/691 (14.3%) of the 
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antimicrobials prescribed, followed by hospitalists (56/691, 8.1%), infectious diseases 
specialists/microbiologists (49/691, 7.1%), emergency room physicians (45/691, 6.5%), 
intensivists (23/691, 3.3%), geriatricians (7/691, 1.0%) and other, undefined (1/691, 0.1%). 
Table 2.  Patient Characteristics 
Categorical variable Number (N=529) Percentage 
Gender   
Female 
Male 
284 
245 
53.7 
46.3 
Admitted to ICU7   
Yes 
No 
48 
481 
9.1 
90.9 
Documented ID8 Consult   
Yes 
No 
63 
466 
11.9 
88.1 
Immunosuppression   
Yes 
No 
79 
450 
14.9 
85.1 
Number of 
antimicrobials/patient 
  
1 
2 
≥ 3 
390 
119 
20 
73.7 
22.5 
3.8 
   
Continuous variable Mean SD9 
Age 67.1 18.8 
Charlson Index 6.2 4.0 
Antimicrobials/patient 1.3 0.56 
 
  
                                                            
7 ICU = Intensive Care Unit 
 
8 ID = Infectious Diseases 
 
9 SD = Standard Deviation 
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Table 3.  Number of Prescribed Antimicrobials by Indication 
Indication  Number (N=691) Percentage 
Treatment 587 85 
Community-acquired infection 
Hospital-acquired infection 
326 
261 
47.2 
37.8 
Prophylaxis 104 15 
Surgical prophylaxis 
Medical prophylaxis 
82 
22 
11.9 
3.2 
   
 
 
Table 4.  Number of Prescribed Antimicrobials by Prescriber Type 
Prescriber type  Number (N=691) Percentage 
Family Medicine 238 34.4 
Surgeon 173 25.0 
Internal Medicine 99 14.3 
Hospitalist 56 8.1 
Infectious 
Diseases/Microbiologist 
49 7.1 
Emergency Room Physician 45 6.5 
Intensivist 23 3.3 
Geriatrician 7 1.0 
Other (not defined) 1 0.1 
 
Variability was seen when an analysis of the proportion of patients who were estimated to be 
on antimicrobial therapy at the time of the PPS was performed, both between regions and 
between zones.10 (Figure 1)
                                                            
10 A zone is defined by a geographically distinct section of the province; each zone is comprised of either a 
university hospital centre or community hospital with tertiary services plus at least one smaller community 
hospital. Each region is comprised of 4 zones. 
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5.2 Patterns of Antimicrobial Utilisation for Prophylaxis Orders 
5.2.1 Medical Prophylaxis orders 
Seventeen patients, 7/17 (41.2%) were women and 10/17 (58.5%) were men, had 22 orders 
defined as medical prophylaxis.  The mean age of this group was 65 years (range 40-92). 
Thirteen patients (76.5%) were immunocompromised based on the US CDC definition as having 
one of: a haematological or solid tumour, having received chemotherapy, having congenital 
immunodeficiency, or long-term immunosuppressive therapy (e.g. equivalent to prednisone 20 
mg/day for 2 weeks or more) or an infection with human immunodeficiency virus (HIV). The 
most frequently prescribed antimicrobials were: cotrimoxazole 7/22, 31.8%, ciprofloxacin 3/22, 
13.6%, fluconazole 2/22, 9.1%, doxycycline 2/22, 9.1%, dapsone  2/22, 9.1%, and voriconazole 
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2/22, 9.1%. The remaining 4/22, 18.2% orders were for rifampin, tetracycline, azythromycin and 
cefoxitin. (Table 5) 
Table 5. Medical Prophylaxis - Antimicrobials Prescribed 
Antimicrobial  Number (n=22) Percentage 
Cotrimoxazole 7 31.8 
Ciprofloxacin 3 13.6 
Fluconazole 2 9.1 
Doxycycline 2 9.1 
Dapsone 2 9.1 
Voriconazole 2 9.1 
Miscellaneous 4 18.2 
 
5.2.2  Surgical Prophylaxis Orders 
Of the 82 antimicrobials prescribed for surgical prophylaxis,  34/82, 41.5% were for orthopaedic 
surgery, 19/82, 23.2% for gastrointestinal surgery , 12/82, 14.6% for cardiovascular surgery, 
7/82 for surgery within the urinary tract and the remaining 4/82, 4.9% were for neurosurgery, 
ear, nose and throat surgery, ophthalmic surgery and one without a documented indication. 
The most frequently prescribed antimicrobials were cefazolin (50/82, 61%), ciprofloxacin (9/82, 
11%), clindamycin (9/82, 11%),  metronidazole (6/82, 7.3%) and cefoxitin (4/82, 4.9%). The 
remaining 4 orders (4/82, 4.9%) were for cephalexin, penicillin, vancomycin and 
piperacillin/tazobactam. (Table 6) 
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Table 6. Surgical Prophylaxis - Antimicrobials Prescribed 
Antimicrobial  Number (n=82) Percentage 
Cefazolin 50 61 
Ciprofloxacin 9 11 
Clindamycin 9 11 
Metronidazole 6 7.3 
Cefoxitin 4 4.9 
Miscellaneous 4 4.9 
 
5.3  Patterns of Antimicrobial Utilisation for Treatment Orders 
Of the 587 antimicrobials prescribed for the treatment of either a community-acquired or a 
hospital-acquired infection,  the top 7 most frequently prescribed classes were the 
fluoroquinolones  (150/587, 25.6%) ,  extended spectrum penicillins (60/587, 10.2%), 
metronidazole (50/587, 8.5%), third-generation cephalosporins (49/587, 8,3%), aminopenicillins 
(46/587, 7.8%), first-generation cephalosporins (34/587, 5.8%) and second-generation 
cephalosporins (31/587, 5.3%). (Table 7) These 7 classes accounted for 71.5% of the 
antimicrobials prescribed for treatment. Sixteen other classes of antimicrobials accounted for 
the remaining 167/587 (28.5%) of orders (see Appendix 7 for further detail) 
Table 7.  Treatment-Prescribed Antimicrobials by Class 
Antimicrobial Class Number (n=587) Percentage 
Fluoroquinolones 150 25.6 
Extended Spectrum Penicillins 60 10.2 
Metronidazole 50 8.5 
3rd Generation Cephalosporins 49 8.3 
Aminopenicillins 46 7.8 
1st Generation Cephalosporins 34 5.8 
2nd Generation Cephalosporins 31 5.3 
Others 167 28.5 
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Overall there were 587 orders for combined community-acquired infections or hospital-
acquired infections. Of these, 113 (19.3%) did not have a documented indication and therefore 
no anatomic site of infection could be assigned. Of the remaining 474 orders,  the top 6 
anatomic sites of infection were: pneumonia (140/474, 29.5%), gastro-intestinal (74/474, 
15.6%), skin and soft tissue (68/474, 14.3%), cystitis (55/474, 11.6%), bronchitis (35/474, 7.4%) 
and bone and joint (22/474, 4.6%) (Table 8) (see Appendix 8 for further detail) 
Table 8.  Anatomical Sites for Community- and Hospital-Acquired Infections 
Anatomic site Number (n=474) Percentage 
Pneumonia 140 29.5 
Gastro-Intestinal 74 15.6 
Skin and Soft Tissue 68 14.3 
Cystitis 55 11.6 
Bronchitis 35 7.4 
Bone and Joint 22 4.6 
Other 80 16.8 
 
The top 6 treatment-prescribed antimicrobials were: ciprofloxacin (95/587, 16.2%), piperacillin-
tazobactam (59/587, 10.1%), metronidazole (50/587, 8.5%), moxifloxacin (43/587, 7.3%), 
amoxicillin (includes amoxicillin-clavulanate) (39/587, 6.6%) and ceftriaxone (38/587, 6.5%) 
(Table 9) (see Appendix 9 for further detail) 
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Table 9.  Treatment Prescribed Antimicrobials 
Antimicrobial Number (n=587) Percentage 
Ciprofloxacin 95 16.2 
Piperacillin-Tazobactam 59 10.1 
Metronidazole 50 8.5 
Moxifloxacin 43 7.3 
Amoxicillin 39 6.6 
Ceftriaxone 38 6.5 
Other 263 44.8 
 
Of the 95 orders identified for ciprofloxacin, 31/95 (32.6%) had no documented indication, 
19/95 (20%) were for the treatment of cystitis, 17/95 (20%) for gastro-intestinal infections, 
9/95 (9.5%) for pneumonia, 7/95 (7.4%) for skin and soft tissue infections, 7/95 (7.4%) for the 
treatment of pyelonephritis and 5/95 (5.4%) for miscellaneous other indications. (Table 7) 
Table 10.  Ciprofloxacin Use by Anatomic Site 
Anatomic Site Number Percentage 
No documented indication 31 32.6 
Cystitis 19 20.0 
Gastro-Intestinal 17 17.9 
Pneumonia 9 9.5 
Skin and Soft Tissue 7 7.4 
Pyelonephritis 7 7.4 
Miscellaneous 5 5.4 
 
5.4 Appropriateness of Prophylaxis Orders 
5.4.1 Appropriateness of Medical Prophylaxis Orders 
The 17 patients who were receiving medical antimicrobial prophylaxis were admitted to 
hospitals for indications which appeared unrelated to the reason they were prescribed 
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antimicrobials for prophylaxis. This was surmised based on the types of treatment 
antimicrobials they received at the time of the PPS and the documented indications for 
this treatment. Limited information was documented regarding the reason for the 
medical prophylaxis. No further appropriateness assessment was made on the medical 
prophylaxis orders due to the lack of documentation and clear guidelines with respect to 
the appropriateness of such orders.  
 5.4.2.  Appropriateness of Surgical Prophylaxis Orders  
Eighty-two antimicrobials were prescribed for surgical prophylaxis (Table 11). These 
orders were categorized based on the following durations: 1 dose only, 24-hour or less, 
greater than 24 hours. Sixty-seven percent of orders were deemed appropriate and 
32.9% inappropriate based on the IDSA 2013 guidelines (http://www.idsociety.org ) that 
suggest that the duration of prophylaxis should be 24 hours or less for most procedures.  
Table 12 provides information regarding the duration of surgical prophylaxis based on 
anatomic site. No other appropriateness assessment was planned for surgical 
prophylaxis orders during this PPS. 
Table 11.  Duration of Surgical Prophylaxis 
Duration of Prophylaxis Number Percentage 
≤ 24 hours 37 45.1 
> 24 hours 27 32.9 
1 dose 18 21.9 
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Table 12.  Duration of Surgical Prophylaxis by Anatomic Site 
Anatomic Site 1 dose   
n (%) 
≤ 24 hours  
n (%) 
> 24 hours  
n (%)  
Total 
Central nervous system 0 (0.0) 0 (0.0) 1 (100) 1 
Cardiovascular 2 (16.7) 8 (66.7) 2 (18.7) 12 
Ear/Nose/Throat 0 (0.0) 0 (0.0) 1 (100) 1 
Eye 0 (0.0) 1 (100) 0 (0.0) 1 
Gastrointestinal 5 (26.3) 2 (10.5) 12 (63.2) 19 
Obstetrics/Gynecology 5 (83.3) 1 (16.7) 0 (0.0) 6 
Bone/Joint 3 (8.9) 25 (73.5) 6 (17.6) 34 
Urinary Tract 2 (33.3) 0 (0.0) 5 (66.7) 7 
Not documented 1 (100) 0 (0.0) 0 (0.0) 1 
 
5.5  Appropriateness of Treatment Orders 
Based on pre-defined criteria, 254/587 (43.3%) of treatment orders were either inappropriate 
134/587, 22.9% or had no documented indication, 120/587, 20.4%. (Table 13) Three hundred 
and thirty-three orders, 56.7%, did not meet any of the inappropriateness criteria.  
Table 13.  Appropriateness of Therapy 
Code Inappropriateness Criteria Number Percentage
A0 Did not meet criteria 333 56.7 
A1 Inappropriate duplication of therapy 22 3.7 
A2 Opportunity to de-escalate 13 2.2 
A3 Bug-drug mismatch 11 1.9 
A4 Inappropriate dose 24 4.1 
A5 Opportunity for IV to PO stepdown 34 5.8 
A6 Inappropriate treatment of bacteriuria 24 4.1 
A7 Inappropriate route 0 0 
A8 Inappropriate 2nd line therapy 0 0 
A9 No documented indication 120 20.4 
 
38 
 
There were significantly more antimicrobial orders that met inappropriateness criteria A1  
through A9 when no infectious diseases service(IDS) (defined as one or more physicians with 
expertise in infectious diseases) was available at the hospital where the data were collected  
(Χ2 = 15.62, df = 1, p<0.001) (Table 14). Of note, at the time of the PPS and currently IDS are 
available only in those hospitals with on-site ID specialists. Telehealth or other off-site 
consultation services are not provided.  
Table 14.  Influence of Infectious Diseases Services (IDS) and Inappropriateness Codes 
 Code A0 
n (%) 
Codes A1-A9 
n (%) 
Totals 
IDS 201 (65.0) 108 (35.0) 309 
No IDS 145 (48.8) 152 (51.2) 297 
Total 346 260 606 
(Χ2 = 15.62, df = 1, p<0.001)  
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CHAPTER 6. DISCUSSION AND RECOMMENDATIONS FOR PRACTICE AND POLICY MAKING 
 
This PPS was performed to assess whether antimicrobial usage within NB hospitals was 
appropriate, based on pre-defined criteria, for the treatment of community- and hospital-
acquired infections or for medical or surgical prophylaxis and to assess whether differences 
exist between  regions and geographic zones as a means to identify targets for AS activities.  
 
No Canadian PPS reports on antimicrobial utilisation with appropriateness assessment were 
found in the literature and therefore comparisons will primarily be made with US, Australian 
and European survey results as their patient populations, while not identical, are more likely to 
resemble those in the Canadian context compared to Asian or Middle-Eastern surveys.  
 
6.1  Burden of Utilisation 
Of the 2244 patients who were admitted to the 21 surveyed hospitals during the survey period, 
529 (23.6%) were on systemic antimicrobials. These data suggest that the burden of 
antimicrobial utilisation in NB hospitals was in the lower spectrum of that generally reported 
elsewhere. PPS performed in several European, Australian and one US university teaching 
hospital report usage ranging from 22.9% up to 48% (average 32%). (29, 39, 54-55, 60-67) The 
one Canadian study that reported on the burden of utilisation (56) reported that 36% of 
patients among the total patients surveyed were on at least one systemic antimicrobial. While 
not reported in either the Canadian or the international literature, it is interesting to note that 
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34.4% of all antimicrobial orders in NB were from members of the Department of Family 
Medicine. This should not be surprising given that within NB hospitals, approximately 30% of 
inpatient care is provided by members of this department.11 An analysis of the proportion of 
patients estimated to be on an antimicrobial at the time of the PPS suggests between-zone and 
between-region variability. No regression analysis was performed to attempt to identify 
variables that could influence these prescribing patterns. Further research would be required to 
understand the root causes of these variations. 
 
6.2 Antimicrobial Utilisation Based on Indications 
A total of 691 antimicrobials were prescribed with 85% of these for the treatment of either 
community-acquired (47.2%) or hospital-acquired infections (37.8%). The remaining 15% were 
for either surgical (11.9%) or medical prophylaxis (3.2%). These findings were similar to those 
reported internationally, ranging from 70% to 84% for treatment indications  and 16% to 30% 
for prophylaxis. (53-54, 62, 66)  Only Ansari and colleagues (54)  specifically reported on the 
rates of antimicrobials used to treat community-acquired infections (48.4%) and hospital 
acquired infections (30%) and for surgical prophylaxis (15%) and medical prophylaxis (6.7%). 
These results are similar to the NB findings.  
 
The most frequent types of infections reported in this PPS included pneumonia (29.5%), gastro-
intestinal infections (15.6%), skin and soft tissue infections (14.3%) and cystitis (11.6%). A study 
                                                            
11 Personal communication, chairs of the Horizon and Vitalité Medical Advisory Committees 
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performed in Northern Ireland  in 4 acute-care hospitals and using a very similar survey (53, 62) 
reported very comparable findings, with respiratory infections being most common (30%) 
followed by gastrointestinal infections (18%), skin and soft tissue infections (18%) and urinary 
tract infections (13%).  Ansani and colleagues reported on the results of a PPS performed in 20 
European hospitals in 2006. (54) Respiratory tract infections was also the most frequent 
indication (28.9%) followed by skin and soft tissue infections (18.8%), intra-abdominal 
infections (12.6%) and urinary tract infections (13.5%). (54) An Australian study comparing 
antimicrobial utilisation in private hospitals and state run hospitals reported that overall, the 
most frequent indications were respiratory infections (31.3%), skin and soft tissue infections 
(17.8%), urinary tract infections (12.1%) and bone and joint infections (12.1%). (60)  Amadeo 
and colleagues (63) performed their PPS in paediatric hospitals; no direct comparison was made 
between their results and the NB results given that only 9 patients in the NB survey were less 
than 19 years of age. Other PPS performed in Europe did not report types of infections being 
treated. (29, 39, 61-62, 64-67) No other Canadian data were available for comparison. 
6.3 Antimicrobial Utilisation Based on Antimicrobial Class 
Fluroroquinolones were the most frequently ordered class of antimicrobials, and ciprofloxacin 
the most frequent of the fluoroquinolones, representing 25.6%  and 16.2% respectively of all 
orders. The next closest class are extended-spectrum penicillins (10.2%). In their PPS for 
nosocomial infections in 7 Canadian hospitals, including one NB hospital, Gravel and colleagues 
reported that the overall most frequent antimicrobials ordered were cephalosporins (11.4%), 
fluoroquinolones (10.6%), metronidazole (6.6%) and penicillins (6.5%). (56) The apparent 
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difference in rates of fluoroquinolone prescribing in NB hospitals compared to the Canadian 
rates from 2002 is worth noting and is troublesome. Most European countries suggested an 
increase in fluoroquinolone use but were well below the rate reported here (range 3.9% to 
14.9%) (29, 39, 53-54, 62, 66-67) save in France where reported rates were similar to NB’s  
(23.6%) (65). This was described as an anomaly compared to the other countries in the 
European Union (EU) and the authors suggested a more focused survey would be required to 
attempt to elucidate the reasons for the variance. (65) This high use of fluoroquinolones in NB 
and in France are of concern since the ESAC and others have reported that an increase in use of 
fluoroquinolones has resulted in significant increases in rates of fluoroquinolone-resistant E. 
coli, Klebsiella pneumoniae and Pseudomonas. (36-38, 54) Fluroroquinolone  and other broad-
spectrum antibiotic use has also been identified as an independent risk factor for the 
development of CDAD. (42) When appropriateness criteria based on the Gyssens criteria (68) 
(see Table 15) were applied, fluoroquinolones have also been found to be an independent risk 
factor for inappropriate prescribing. (29) While different than the inappropriateness criteria 
applied in our survey, this could be an area of interest for future research. Seven classes of 
antimicrobials accounted for 72% of the orders. Sixteen classes therefore accounted for the 
remaining 28% of orders which suggests considerable variability in antimicrobials prescribed.  
6.4 Appropriateness of Antimicrobial Utilisation 
Although 587 antimicrobial orders were reviewed that were ordered for the treatment of either 
community- or hospital-acquired infections, 333 (56.7%) of these orders did not meet any of 
the applied inappropriateness criteria and were therefore not evaluable. A further 20.4% had 
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no documented indication that could be identified in the chart therefore limiting the data 
available for assessment.  In comparing to similar surveys done elsewhere, lack of 
documentation has been identified as a key target for intervention with rates averaging 25%, 
above the NB incident of 20.4% (range 15.7% to 42%). (53, 55, 60-62, 64, 66)  While apparently 
better than the rates reported in the literature, efforts to improve documentation should also 
be included in NB’s stewardship efforts. 
 
The remaining 22.6% of orders fell in one of 6 other inappropriateness criteria: opportunity for 
IV to PO stepdown (5.8%), inappropriate dose (4.1%), inappropriate treatment of bacteriuria 
(4.1%), inappropriate antimicrobial therapy duplication (3.7%), opportunity to de-escalate 
(2.2%) and bug-drug mismatch (1.9%) and are considered appropriate for targeted AS 
interventions. No comparison could be made with European and Australian published data in 
regards to the inappropriateness criteria used in this PPS as the criteria they used were 
dissimilar or appropriateness of utilisation was not one of the objectives of the study. One PPS 
performed in a tertiary care hospital in the US and available in abstract form only (57) used 
somewhat similar inappropriateness criteria and reported 22% of their orders were either 
unnecessary or overly broad. Within this 22% the most common reason for unnecessary 
antimicrobial use was for the treatment of asymptomatic bacteriuria (5.6%), failure to de-
escalate (4.5%) and duplication of therapy (2.1%).  This PPS did not report on such criteria as 
appropriateness of dosing and IV to PO stepdown. Comparison with the NB data must be made 
with caution because of these differences in criteria used but also since these data are from a 
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single tertiary centre and insufficient information in available to compare the patient 
characteristics and the hospital case load to enable an assessment of their degree of similarity.  
Regardless of whether these results are comparable, the NB data point to areas of potential 
improvement and various possible strategies requiring various levels of resources including 
antibiotic policies, audit and feedback, clinical guidelines and the enabling of delegated 
functions to other members of the care team including clinical pharmacists.  
 
It is generally accepted that there is no clinical reason to extend surgical prophylaxis beyond 24 
hours post-surgery. (http://www.idsociety.org , 54) The ESAC group has gone so far as to 
recommend that “the target rate for duration of prophylaxis > 24-hours should be zero for all 
specialties.” (54) Results of this survey indicate that 33% of the antimicrobial orders for surgical 
prophylaxis in NB hospitals were for a duration greater than 24 hours. In comparison, rates 
reported internationally range from 0 to 70%. (53, 54, 60-61, 63-67)  From this comparison, NB 
results fall within the median of the reported rates; making surgical prophylaxis an appropriate 
target for stewardship interventions. Countries where surgical prophylaxis guidelines were used 
reported good adherence to the recommendations. (53, 61)  
 
6.5  Study Limitations 
This PPS is deemed exploratory as it only captures data from a moment in time and may not be 
reflective of the overall antimicrobial prescribing trends within NB’s health networks. (69) No 
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definitive statement can be made based on the results of the survey but they may be indicative 
of where further efforts should be focussed. (69)  While the overall number of patients who 
were on antimicrobials at the time of the survey (529/2244, 23.6%) is within the generally 
reported range, it does lie in the lower end of this range (22.9% - 48%). It may be that the 
timing of the survey (June-August) resulted in numbers that could have been strongly 
influenced by the practices of select clinicians or caseloads or practice sites.  Not all surgical 
specialties were represented in the case mix identified during this PPS. Some NB hospitals close 
surgical suites or decrease surgical suite utilisation, therefore limiting the number of elective 
procedures performed. A certain degree of subjective judgement was used in attributing the 
inappropriateness criteria for the treatment antimicrobials and no inter-rater reliability test was 
performed to identify whether this was significant. No costing analysis was performed 
regarding possible savings should unnecessary therapies be prevented. Insufficient data were 
collected to perform such an analysis given the nature of a PPS. Actual medication utilisation 
would be necessary to assess potential savings i.e. the actual duration of the therapy and the 
doses used and this was deemed to be beyond the scope of this project. Fifty-seven percent of 
the orders retrieved “did not meet criteria” for evaluation of appropriateness. In this survey, 
“did not meet criteria” was not synonymous with either “appropriate” or “inappropriate”. A 
broader choice of inappropriateness criteria may have captured some of these orders and 
therefore could have added to the robustness of the results. The use of the Gyssens criteria (68) 
(see Table 12) to evaluate appropriateness of antimicrobial utilisation may have resulted in an 
increase in the number of reported inappropriate orders. 
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Table 15.  Gyssens Criteria 
1. Correct decision (appropriate use) 
• No AMT12 and no infection and no AMT needed 
• No AMT and infection and no AMT needed 
• AMT and infection and appropriate choice and appropriate use 
2. Incorrect decision (inappropriate use) 
• No AMT and infection and AMT needed 
• AMT and no infection and no prophylaxis and no AMT needed 
• No AMT and no infection and prophylaxis needed 
3. Incorrect choice (inappropriate use) 
• Divergence from guidelines 
4. Missing data (insufficient information) 
• No AMT and not enough diagnostic information about infection 
• Infection and not enough diagnostic information if AMT is 
needed 
• AMT and not enough diagnostic information about infection 
• Infection and not enough information about AMT 
 
6.6 Study Strengths 
While much work has been done in Canadian hospitals in regards to AS activities, most of this 
work has occurred in the intensive care area and in hospitals in other provinces and may not be 
generalisable to all hospital-care settings or to NB. (51-52) The most significant strength of this 
survey is the fact that it was done in NB to be used in NB and all eligible hospitals were 
included. It provides province-wide information over the full range of medical and surgical 
services. The inappropriateness criteria were pre-defined based on previous work done 
elsewhere and the design of the survey was based on work done extensively in Europe. All 
inappropriateness criteria were evaluated by two sets of reviewers: clinical pharmacists with 
extensive knowledge of antimicrobial therapy and infectious diseases specialty physicians. 
                                                            
12 AMT = antimicrobial therapy 
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6.7 Future Research 
Further research would be needed to attempt to investigate and evaluate the contribution of 
potential factors that may lead to deviation from optimal prescribing such as the extensive 
variability in the use of antimicrobials by class, the large percentage of treatment orders that 
were without an indication, the large percentage of orders for antimicrobial prophylaxis that 
had a duration of greater than 24 hours and the suggested inter-zone and inter-regional 
incidence of antimicrobial prescribing. 
6.8 Recommendations for Practice and Policy Making 
The results of this PPS support that AS efforts in NB should be focused on enabling IV to PO 
stepdown, de-escalation of therapy, appropriateness of dosing, halting treatment of 
asymptomatic bacteriuria in non-pregnant patients, halting of unnecessary duplicate therapies, 
improving documentation of indications within the patient record, improving adherence to 
surgical prophylaxis guidelines and improving antimicrobial selection overall.  Specific efforts 
should be directed at decreasing the overall use of fluoroquinolones and other broad-spectrum 
antimicrobials when possible. Decision makers should focus their efforts on AS strategies that 
are supported by evidence such as antibiotic use policies, audit and feedback processes, clinical 
guidelines and the development of  acceptable delegated function which enable other 
members of the care team to directly intervene on orders that do not meet pre-defined criteria 
for appropriateness.  Furthermore, the results of this PPS indicate that in NB, efforts should  
also focus on increasing prescriber awareness on the importance of adherence to 
documentation standards, the risk of high rates of fluoroquinolone prescribing and prolonged 
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surgical prophylaxis i.e. increased antimicrobial resistance and enabling pathogenic selection.  
Resources should be sought to increase the number of infectious diseases specialists available 
to support prescribers. The PPS showed that there is a significant association between the 
availability of an infectious diseases specialist and appropriateness of prescribing, i.e., the 
presence of and infection diseases specialist resulted in fewer inappropriate treatment orders. 
Because of the important impact of family physicians on in-hospital care and the fact that they 
were the most frequent prescribers (34.4%), specific efforts should be directed towards 
providing this group of prescribers with tools to assist in optimizing antimicrobial prescribing. 
 
Results of the PPS were presented to the NB Anti-Infective Stewardship Committee, the 
Horizon Health Network Regional Medical Advisory Committee, the Vitalité Health Network 
Regional Medical Advisory Committee and the Infectious Diseases specialists groups, various 
other physician groups,  the Canadian Society of Hospital Pharmacists (CSHP) NB Branch annual 
education session (Moncton, NB) and the Dr. Donald MacLellan Research Day (Moncton, NB). 
Poster presentations were given at the CSHP National Annual Summer Education Session 
(Calgary, AB), the Canadian Agency for Drugs and Technologies in Health Annual Symposium 
(Gatineau, QC) the Capital Health Pharmacy Research and Education Day (Halifax, NS) and the 
Interprofessional Health Research Day (Saint John, NB). 
 
Since the first presentation  of the results of this PPS, several actions have been undertaken: a 
dedicated  antimicrobial stewardship website is now available on the two regional Intranet 
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systems and four NB treatment guidelines have been developed and are currently in use: an 
provincial community-acquired pneumonia pathway, a provincial skin and soft tissue infections 
guidelines, a new urinary tract infections guideline with an emphasis towards using 
ciprofloxacin exclusively for the treatment of pyelonephritis  if possible and a new Clostridium 
difficile treatment guideline. Three other provincial guidelines are in progress: an acute sinusitis 
treatment guideline, an acute exacerbation of chronic obstructive pulmonary disease treatment 
guideline and an intra-abdominal/diverticulitis treatment guideline. As well, an antimicrobial IV 
to PO conversion policy has been developed that enables hospital pharmacists throughout the 
province and other members of the healthcare team to step patients down to oral therapy 
when appropriate and safe. Two other studies have also been performed to add to the 
information derived from this PPS: a study of surgical prophylaxis  in the larger Horizon 
hospitals with a broader range of inappropriateness criteria and a study to investigate the 
management of urinary track infections within Horizon hospitals.  
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CHAPTER 7. CONCLUSIONS 
7.1  Conclusions 
To effectively influence prescribing practices, institutions must aim at providing local utilisation 
evidence and relate this information to their clinicians. (9, 61) This PPS performed in NB 
hospitals provides contextual evidence supporting AS efforts enabling IV to PO stepdown, de-
escalation, appropriate dosing, halting treatment of asymptomatic bacteriuria, halting 
unnecessary duplicate therapies, improving documentation, improving adherence to surgical 
prophylaxis guidelines and improving antimicrobial selection. The availability of an infectious 
diseases specialist was found to be statistically related to improved overall appropriateness of 
prescribing.  
 
The results of this PPS indicate that the burden of antimicrobial utilisation in NB hospitals is 
within the lower range of that reported elsewhere. Antimicrobial utilisation by indication was 
similar to that reported elsewhere, with the majority for the treatment of either community-
acquired infections or hospital-acquired infections and the remaining for surgical or medical 
prophylaxis. As well, the most frequent indications for antimicrobial therapy are similar to 
those reported internationally, with respiratory tract infections being the most common 
indication followed by gastrointestinal infections, skin and soft tissue infections and cystitis. 
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Fluroquinolones were found to be the most frequently prescribed class of drugs in NB hospitals. 
Given be that use of fluoroquinolones and ciprofloxacin in particular have been identified as  
independent risk factors for the development of multi-drug resistant organisms and in the 
selection of pathogenic organisms, efforts to modify prescribing patterns to limit the use of this 
class of antimicrobials must be supported and sustained. While not significantly different from 
that reported in the literature, lack of documentation is noteworthy and efforts to promote 
improvement should be considered essential. Efforts should also be directed towards improving 
compliance with recommended guidelines regarding use of antimicrobials in surgical 
prophylaxis.  
Since receiving the results of this PPS, several changes have been implemented within NB 
hospitals. Regular repeated PPS would be an effective tool to evaluated the effectiveness of 
these changes. 
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APPENDIX 1 
ANTI-INFECTIVE STEWARDSHIP COMMITTEE TERMS OF REFERENCE 
NB Provincial Health Authorities Anti-infective Stewardship Committee (ASC)  
(Sub-committee to Drugs and Therapeutics (D&T) Committee) 
Terms of Reference 
 
PURPOSE 
Makes recommendations to the Provincial D&T Committee regarding the formulary of anti-infective 
pharmaceuticals available for use within the New Brunswick regional health authorities, i.e. Vitalité 
Health Network (Vitalité) and Horizon Health Network (Horizon) including conditions and/or criteria for 
use where appropriate which reflects rational, evidence-informed, safe and cost-effective therapy.  
Advises on all matters relating to the use of anti-infective pharmaceuticals within the regional health 
authorities. 
 
VALUES 
Evidence-informed decision making: The committee ensures that decisions are supported with the best 
available evidence and in consideration of the experiences of other jurisdictions.  
Decision making criteria: The committee ensures that decisions support effective therapy consistent 
with best practice and evidence considering the needs of clients, staff, other service providers, and 
prescribing medical professionals, as well as safety, effectiveness, cost and the need to avoid product 
duplication13. 
Provincial Perspective: The committee includes representation from Vitalité and Horizon to ensure the 
committee structure is representative of each RHA.  
 
COMPOSITION  
The members of the committee are appointed by the D&T Committee with the Chair of the ASC, or at 
least one of the members of the committee, also being a member of the D&T Committee.   
                                                            
13 Accreditation Canada Medication Management Standards 2010 
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Membership:  
Chair (may be one of the following members) 
Infectious Diseases physicians (3; with at least one from each RHA) 
Laboratory Medicine Microbiology representative (2; one from each RHA) 
Family Physician representative (2; one from each RHA) 
Public Health representative (2; one from each RHA) 
Infection Control representative (2; one from each RHA) 
Drug Use Evaluation pharmacist (2; one from each RHA) 
Clinical Staff pharmacist with speciality or interest in infectious disease (2; one from each RHA) 
 
The committee has the authority to consult any member of the medical or regional health authority staff 
to act in an advisory capacity. 
 
CONFLICT OF INTEREST DISCLOSURE 
All members will be required to declare any conflict of interest as per the Provincial D&T Committee 
Conflict of Interest Guidelines.  Conflict of interest declarations can be made at the meetings or prior to 
the meeting by notifying the Chair via fax or email.  
The chair has the authority to determine if the circumstances or interests of a participant amount to a 
conflict of interest in respect to a submission that is before the committee.  Participants shall not be 
involved in a submission in which they have sponsorship.   
Names of members who have a conflict of interest shall be documented in the minutes. 
 
FUNCTION 
1. To make recommendations to the D&T Committee regarding the use (rationale, cost effectiveness 
and monitoring) of all anti-infective pharmaceuticals. 
 
xv 
 
2. To undertake evidence-based evaluation of requests for changes to the Formulary with regard to 
anti-infective pharmaceuticals, including additions, deletions and criteria for use, and make 
recommendations to the D&T committee in this regard.  
 
3. To recommend criteria for use, restrictions and policy and procedures for selected anti-infective 
pharmaceuticals to ensure safe and appropriate use within the regional health authorities.   
 
4. To undertake regular review of the formulary, including drug utilization to ensure the anti-infective 
pharmaceuticals available are the most clinically appropriate (with regard to efficacy, toxicity and 
resistance patterns) and cost-effective to serve the patient population, and to make appropriate 
recommendations to the D&T Committee. 
 
5. To review non-formulary drug utilization of anti-infective pharmaceuticals and make 
recommendations to the D&T committee for appropriate adjustments to the formulary. 
 
6. To undertake regular evidence-informed reviews of RHA protocols that contain or are related to use 
of anti-infective pharmaceuticals (including but not limited to criteria for use, treatment guidelines, 
clinical order sets, pre-printed orders, etc.). 
 
7. To monitor the patterns of sensitivity and resistance to anti-infective pharmaceuticals and to initiate 
appropriate drug use evaluation activities as needed in consultation with the D&T Committee. 
 
8. To assist in implementation of education and control measures designed to improve the 
appropriateness, safety and cost-effectiveness of anti-infective use. 
 
9. To provide guidance from a laboratory perspective with regards to current testing methodologies 
and options for testing and therapeutic monitoring that will influence formulary and anti-infective 
therapy decisions. 
 
10. To incorporate the use of high-quality evidence-based resources in decision-making, including but 
not limited to Canadian Agency of Drugs and Technologies in Health (CADTH), Oregon Health and 
Science University’s Drug Effectiveness Review Project (DERP) and Quebec’s le Conceal des 
Medicaments. 
 
 
MEETINGS AND MINUTES 
The committee shall meet at least nine times per year at the call of the chair.  
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The committee shall maintain a permanent record of its proceedings and actions.  
 
Quorum 
A majority of the membership will constitute a quorum 
 
Remuneration/Expenses 
Fee-for-service physicians will be remunerated in accordance with Department of Health administrative 
policy and have travel expenses reimbursed in accordance with the provincial government travel policy. 
Salaried physicians will have travel expenses reimbursed in accordance with the provincial government 
travel policy. 
Regional Health Authority and Department of Health personnel will have travel expenses reimbursed in 
accordance with the provincial government travel policy by their respective organizations.   
Other committee members will have travel expenses reimbursed in accordance with the provincial 
government travel policy. 
 
Accountability (reporting) 
The Anti-infective Stewardship Sub-Committee reports to the Provincial Drugs and Therapeutics 
Committee.  
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APPENDIX 2 
Point Prevalence Survey Data Collection Form  
 
Hospital:_____________ 
Hospital Code:_________ 
Number of Beds:________ 
Tertiary Centre: Yes___  No___ 
ID Service available on-site: Yes___  No___ 
Microbiology Support on-site: Yes___  No___ 
 
Administrative Unit Total # of Pts on Unit on Survey Day 
Total # of Pts on 
Antimicrobial Therapy 
on Survey Day 
Survey 
Date 
(d/m/y) 
Comments 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
 
xviii
Point Prevalence Survey Data Collection Form – Patient Data 
 
* Survey Code (Hospital #/ Survey #/ Patient initials ________________ * Auditor____________ 
*Date of admission (D/M/Y) ________* Survey date (D/M/Y) ________ * Nursing Unit________ 
*MRN __________ * Gender (M/F) _________ * Age______ * Weight ___________ 
* ICU Admission: Yes___ No___ * Mechanical Ventilation: Yes ___ No ___   
* Attending Service__________ * Documented ID Consult (written or verbal): Yes___ No ___ 
*Urinary Catheter1 Yes ___ No ___  
* Allergy2 *Reaction 
  
  
  
  
 
 
Age Adjusted Charlson Co-Morbidity Index3 ______  
 
  Myocardial Infarction4 
 
  Congestive Heart Failure   Peripheral Vascular Disease5
  Stroke (Cerebrovascular 
disease)6  
  Dementia   Chronic Obstructive 
Pulmonary Disease (COPD) 
 
  Connective Tissue Disorder 
 
  Peptic Ulcer Disease7   Mild Liver Disease8 
  Diabetes 
 
  Hemiplegia   Renal disease (eGFR <60) 
  Diabetes/end organ damage 
 
  Any tumour (within 5 years)   Leukemia 
  Lymphoma9 
 
  Mod – Severe liver disease10   Metastatic solid tumour 
  AIDS 
 
  
 
Immunosuppression11  Yes ___ No ___ Reason for Immunosuppression: ___________________ 
MDRD or eGFR: ______mL/min (most recent) 
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xx
Explanatory Notes 
  
1
To locate information refer to nursing notes 
2 To locate information refer to physician order sheet, EMR or Home medication reconciliation form 
3 To locate information refer to History and Physical section of the chart, Progress Notes or Consult Notes (Tim to 
calculate final index score). 
4 Myocardial infarction includes patients with 1 or more definite or probable MI resulting in hospitalization, ECG 
changes and/or enzyme changes at any time. 
5 Peripheral vascular disease includes patients with intermittent claudication or those who had a bypass for 
arterial insufficiency, those with gangrene or acute arterial insufficiency, and those with an untreated thoracic or 
abdominal aneurysm (6 cm or more). 
6 Cerebrovascular disease includes patients with a history of a cerebrovascular accident with major but also minor 
or no residua and transient ischemic attacks. 
7 Peptic ulcer disease consists of patients who have required treatment for ulcer disease, including those who 
have bled from ulcers. 
8 Mild liver disease consists of cirrhosis without portal hypertension or chronic hepatitis.  
9 Lymphoma includes patients with Hodgkins, lymphosarcoma, Waldenstroms’s macroglobulinemia, myeloma and 
other lymphoma 
10 Moderate liver disease consists of cirrhosis with portal hypertension without variceal bleeding. Severe liver 
disease consists of patient with cirrhosis with portal hypertension and a history of variceal bleeding. 
11
 As per CDC defined severe immunodeficiency: haematological and solid tumours, receipt of chemotherapy, 
congenital immunodeficiency, or long-term immunosuppressive therapy (e.g. equivalent to prednisone 20 mg/day 
for 2 weeks or more) or patients with HIV infection with CD4 count < 200 
12 Grams per dose; for combination products record the total dose prescribed  
(e.g. Amoxi/Clav: 500/125 = 0.625 g; Co-trimoxazole DS = 0.96 g) 
13 Provide fractions of dose when necessary (e.g. q18h = 1.5 doses/day; q36h = 0.67 dose/day; q48 h = 0.5 
dose/day) 
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14 IV, IM PO 
15 From clinical order set, pathway or pre-printed orders when can be assessed 
16 Diagnosis or indication for therapy was recorded in the notes or consult when started 
17 See list for standardized nomenclature for diagnosis 
18
 Prescriber:  
Family Medicine FM Infectious Disease Specialist/ 
Microbiologist 
 
ID Intensivist ICU
Internal Medicine IM Surgeon
 
S Paediatrician P
Geriatrician G Pharmacist
 
RPh Nurse Practitioner NP
 
19 Indication Codes 
A: Community Acquired Infection Symptoms or antimicrobial started < 48 hours from admission 
B: Hospital Acquired Infection Symptoms or antimicrobial started > 48 hours from admission 
C: Surgical Prophylaxis C1: Single dose C2: ≤ 24 hrs C3: > 24 hrs 
D: Medical Prophylaxis  
 
20 Relevant culture taken before antimicrobial treatment was started, representative of the site being treated. 
Print copies of culture results taken within 120 hours (5 days) of start of therapy and attach to form. 
21 Assessment regarding appropriateness of therapy or potential for stewardship interventions, more than 1 may 
apply. To be completed by investigators following data collection. 
 
22 To locate information refer to nurses notes, graphic, EMR 
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APPENDIX 3 
Definitions 
Bug-Drug Mismatch Patient on an antimicrobial to which the presumed causative 
organism is resistant based on relevant culture and sensitivity 
reports 
 
Community Acquired Infection Symptoms of antimicrobial therapy for presumed infection 
started < 48 hours after patient was admitted to hospital 
 
Hospital Acquired Infection Symptoms start > 48 hrs after admission to hospital and/or 
associated with treatments in performed hospital  
 
Immunocompromised As per CDC14 defined severe immunodeficiency: 
haematological and solid tumours, receipt of chemotherapy, 
congenital immunodeficiency, or long-term 
immunosuppressive therapy (e.g. equivalent to prednisone 20 
mg per day for 2 weeks or more) or patients with HIV 
infection with CD4 count < 200/mm3 
 
Inappropriate Dose Based on patient characteristics (e.g. eGFR) and/or indication 
(e.g. Meningitis dosing) 
 
Inappropriate Route Inappropriate route for indication being treated (e.g. oral 
route for endocarditis, CNS infection, deep abscess, high risk 
febrile neutropenia, etc.) 
 
Inappropriate Therapy Duplication Inappropriate double coverage (e.g. dual β-lactam therapy, 
double coverage when culture and sensitivity results 
available) 
 
Inappropriate Treatment of 
Asymptomatic Bacteruria 
Treatment of a positive urine culture and sensitivity in a 
patient without symptoms or signs referable to a urinary tract 
infection (fever; increased WBC; urinary frequency, urgency, 
and dysuria; suprapubic pain; costovertebral angle 
pain/tenderness) and patient not pregnant, having recent or 
planned urological procedure with mucosal bleeding or 
TURP15 
 
Opportunity for De-escalation Relevant culture and sensitivity report available that indicates 
appropriate de-escalation option  to a narrower antimicrobial 
spectrum antimicrobial agent (if allergy profile permits) 
                                                            
14 CDC = Centre for Disease Control www.cdc.gov  
15 TURP = Trans-Urethral Resection of the Prostate 
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Opportunity for IV to PO Conversion An appropriate oral option exist and patient has met the 
following criteria for IV to PO conversion: has improved 
clinically (WBC ↓, haemodynamically stable, improved signs 
& symptoms) and has been afebrile for at least 48 hours; is 
tolerating oral nutrition, enteral feeds and/or other oral 
medications; is not showing evidence of malabsorption (e.g. 
diarrhoea/vomiting) and none of the following are present: 
continuous nasogastric suctioning, gastrectomy, 
malabsorption syndrome (i.e. short gut), GI obstruction, or 
ileostomy; is not being treated for an indication where 
parenteral therapy is clinically indicated (e.g. endocarditis, 
CNS infection, osteomyelitis, bacteraemia, abscess, cystic 
fibrosis); and does not have febrile neutropenia 
 
Prescriber Family Practice Physician, Internal Medicine Specialist, 
Infectious Disease Specialist/Microbiologist, Surgeon, 
Intensivist, Paediatrician, Geriatrician, Hospitalist, Pharmacist, 
Nurse Practitioner 
 
Relevant culture Sample taken before or during antimicrobial treatment and 
representative of the site of presumed infection being treated
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APPENDIX 4 
Inappropriateness Criteria – Treatment and Medical Prophylaxis 
A0: Does not meet other criteria 
 
Does not meet other assessment criteria
A1: Inappropriate Therapy Duplication e.g. Dual β-lactam therapy; inappropriate double coverage (i.e. 
double coverage when culture and sensitivity results available) 
 
A2: Opportunity for De-escalation Relevant C&S results available for de-escalation to a more 
narrow antimicrobial agent (if allergy profile permits) 
 
A3: Bug-Drug Mismatch Patient on antimicrobial to which relevant C&S reports show 
resistance 
 
A4: Inappropriate Dose Inappropriate dose based on patient characteristics (e.g. eGFR)
and/or indication (e.g. meningitis dosing) 
 
A5: Opportunity for IV to PO Apply to each antimicrobial therapy patient is receiving and to 
where appropriate oral option is available (see p.2 stepdown 
criteria on Patient data collection form) 
 
A6: Inappropriate Treatment for 
Asymptomatic Bacteruria 
Treatment of a positive urine C&S in a patient without S&S 
referable to a urinary tract infection (see p. 2  UTI criteria on 
Patient data collection form) 
 
A7: Inappropriate route Inappropriate route for indication being treated (e.g. oral route 
for treatment of endocarditis, central nervous system infection, 
deep abscess, high risk febrile neutropenia, etc.) 
 
A8: Inappropriate 2nd Line Therapy Inappropriate use of a second line antimicrobial therapy based 
on erroneous allergy information 
 
A9: No Indication Therapy with no documented or identifiable indication 
 
 
Inappropriateness Criteria for Surgical Prophylaxis 
C3: Duration longer than 24 hours IDSA does not support duration longer than 24 hours for most surgical 
prophylaxis (www.idssociety.org ) 
 
C2: Duration of 24 hours or less Acceptable duration based on IDSA 
 
C1: One pre-operative dose Acceptable duration based on IDSA 
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APPENDIX 5 
Research Ethics Board Approval Letter – 
Horizon Health Network 
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APPENDIX 6 
Research Ethics Board Approval Letter – Vitalité Health Network 
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APPENDIX 7 
Antimicrobials  Prescribed for the Treatment of Community- and  
Hospital-Acquired Infections by Antimicrobial Class 
AHFS Class Name Number %
8:12:18 Quinolones 150 25.6%
8:12:16:16 Extended Spectrum Penicillins 60 10.2%
8:31:32 Metronidazole 50 8.5%
8:12:06:23 3rd Generation Cephalosporins 49 8.3%
8:12:16:08 Aminopenicillins 46 7.8%
8:12:06:04 1st Generation Cephalosporins 34 5.8%
8:12:06:08 2nd Generation Cephalosporins 31 5.3%
8:12:12:92 Other Macrolides 27 4.6%
8:12:28:16 Glycopeptides 21 3.6%
8:14:08 Azoles 18 3.1%
8:12:28:20 Clindamycin 16 2.7%
8:12:07:08 Carbapenems 15 2.6%
8:12:20 Sulfonamides 15 2.6%
8:12:02 Aminoglycosides 12 2.0%
8:12:24 Tetracyclines 11 1.9%
08:12:16:12 Penicillinase Resistant Penicillins 8 1.4%
8:36 Urinary Anti-Infectives 7 1.2%
8:12:16:04 Natural Penicillins 7 1.2%
8:12:12:04 Erythromycin 4 0.7%
8:14:16 Echinocandins 3 0.5%
8:16;92 Dapsone 1 0.2%
8:12:28:24 Linezolid 1 0.2%
8:14:02 Terbinafine 1 0.2%
  587 100.0%
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APPENDIX 8 
Anatomic Sites for  Community- and Hospital-Acquired Infections 
Site Number % 
PNEU 140 29.5% 
GI 74 15.6% 
SST 68 14.3% 
Cyst 55 11.6% 
BRON 35 7.4% 
BJ 22 4.6% 
BAC 18 3.8% 
Pye 14 2.9% 
SIRS 13 2.7% 
IA 12 2.5% 
ENT 11 2.3% 
CV 7 1.5% 
OBGY 2 0.4% 
CNS 2 0.4% 
Misc 1 0.2% 
 474 99.8% 
 
Definitions (Ansari 2009) 
Code Definition Code Definition 
PNEU Pneumonia IA Intra-abdominal infection 
GI Gastrointestinal infection ENT Ear/Nose/Throat infection 
SST Skin and soft tissue infection SST Skin and soft tissue infection 
Cyst Cystitis CV Cardiovascular infection 
BRON Bronchitis BRON Bronchitis
BJ Bone and Joint OBGY Obstetrical or gynaecological infection 
BAC Bacteraemia CNS Central nervous system infection 
Pye Pyelonephritis Misc Miscellaneous
SIRS Systemic inflammatory response
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APPENDIX 9 
Treatment-Prescribed Antimicrobials 
Antimicrobial Number %
Ciprofloxacin 95 16.2%
Piperacillin-Tazobactam 59 10.1%
Metronidazole 50 8.5%
Moxifloxacin 43 7.3%
Amoxicillin 39 6.6%
Ceftriazone 38 6.5%
Cefuroxine 30 5.1%
Cefazolin 23 3.9%
Azithromycin 21 3.6%
Vancomycin 21 3.6%
Fluconazole 17 2.9%
Clindamycin 16 2.7%
Cotrimoxazole 15 2.6%
Cephalexin 13 2.2%
Doxycycline 11 1.9%
Gentamicin 9 1.5%
Levofloxacin 9 1.5%
Ceftazidime 8 1.4%
Cloxacillin 8 1.4%
Imipenem 8 1.4%
Ampicillin 7 1.2%
Clarithromycin 6 1.0%
Meropenem 6 1.0%
Nitrofurantoin 6 1.0%
Penicillin 5 0.9%
Erythromycin 4 0.7%
Caspofungin 3 0.5%
Norfloxacin 3 0.5%
Cefotaxime 2 0.3%
Tobramycin 2 0.3%
Amikacin 1 0.2%
Cefixime 1 0.2%
Cefprozil 1 0.2%
Dapsone 1 0.2%
Ertapenem 1 0.2%
Linezolid 1 0.2%
xxx 
 
Terbinafine 1 0.2%
Ticarcillin 1 0.2%
Trimethoprim 1 0.2%
Voriconazole 1 0.2%
 
 
 
 
